Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | SNCA | P37840 | 11/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341583 | 0.86 | MTNR1A (0.70) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL5437839 | 0.85 | MTNR1A (0.68) | MTNR1AMTNR1BNQO2TRPV1HIF1A | |
| SCHEMBL6076123 | 0.85 | MTNR1A (0.69) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL7017220 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL5344432 | 0.78 | MTNR1A (0.63) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL6077016 | 0.77 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2TRPV1HIF1A | |
| SCHEMBL9424922 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL4408801 | 0.76 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL5598218 | 0.76 | HIF1A (0.85) | TRPV1HIF1A | |
| SCHEMBL7614084 | 0.76 | TRPV1 (0.55) | MTNR1AMTNR1BNQO2TRPV1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885MTNR1B 414/4885NQO2 66/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | MTNR1A 465/4885MTNR1B 414/4885NQO2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.